跳至主導覽 跳至搜尋 跳過主要內容

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry

  • Te Sheng Chang
  • , Chung Feng Huang
  • , Hsing Tao Kuo
  • , Ching Chu Lo
  • , Chien Wei Huang
  • , Lee Won Chong
  • , Pin Nan Cheng
  • , Ming Lun Yeh
  • , Cheng Yuan Peng
  • , Chien Yu Cheng
  • , Jee Fu Huang
  • , Ming Jong Bair
  • , Chih Lang Lin
  • , Chi Chieh Yang
  • , Szu Jen Wang
  • , Tsai Yuan Hsieh
  • , Tzong Hsi Lee
  • , Pei Lun Lee
  • , Wen Chih Wu
  • , Chih Lin Lin
  • Wei Wen Su, Sheng Shun Yang, Chia Chi Wang, Jui Ting Hu, Lein Ray Mo, Chun Ting Chen, Yi Hsiang Huang, Chun Chao Chang, Chia Sheng Huang, Guei Ying Chen, Chien Neng Kao, Chi Ming Tai, Chun Jen Liu, Mei Hsuan Lee, Pei Chien Tsai, Chia Yen Dai, Jia Horng Kao, Han Chieh Lin, Wang Long Chuang, Chi Yi Chen, Kuo Chih Tseng, Chao Hung Hung*, Ming Lung Yu*
*此作品的通信作者
  • Chang Gung Memorial Hospital
  • Kaohsiung Medical University
  • Chi-Mei Medical Center
  • St. Martin De Porres Hospital
  • Kaohsiung Armed Forces General Hospital
  • Shin Kong Wu Ho-Su Memorial Hospital
  • Fu Jen Catholic University
  • National Cheng Kung University
  • China Medical University Taichung
  • Tao-Yuan General Hospital
  • Mackay Memorial Hospital Taiwan
  • Chang Gung University
  • Show-Chwan Memorial Hospital Taiwan
  • Yuan's General Hospital
  • Triservice General Hospital Taiwan
  • Far Eastern Memorial Hospital
  • Wu Wen-Chih Clinic
  • Taipei City Hospital
  • Changhua Christian Hospital
  • Veterans General Hospital-Taichung Taiwan
  • National Chung Hsing University
  • Tzu Chi University
  • Cathay General Hospital Taiwan
  • Tainan Municipal Hospital
  • Veterans General Hospital-Taipei
  • National Yang Ming Chiao Tung University
  • Taipei Medical University
  • Yang Ming Hospital
  • Penghu Hospital
  • National Taiwan University
  • I-Shou University
  • Chia-Yi Christian Hospital
  • Buddhist Tzu Chi Medical Foundation
  • National Sun Yat-sen University

研究成果: 期刊稿件 › 文章 › 同儕審查

13 引文 斯高帕斯(Scopus)

摘要

Background: Large-scale real-world data of the 8-week glecaprevir/pibrentasvir (GLE/PIB) therapy for treatment-naïve patients of chronic hepatitis C virus (HCV) infection with compensated cirrhosis is scarce. Methods: The TASL HCV Registry (TACR) is an ongoing nationwide registry program that aims to set up a database and biobank of patients with chronic HCV infection in Taiwan. In this study, data were analyzed as of 31 October 2021 for treatment-naïve HCV patients with compensated cirrhosis receiving 8-week GLE/PIB therapy. Effectiveness reported as sustained virologic response at off-therapy week 12 (SVR12) and safety profiles were assessed. Patient characteristics potentially related to SVR12 were also evaluated. Results: Of the 301 patients enrolled, 275 had available SVR12 data. The SVR12 rate was 98.2% (270/275) in the modified intention-to-treat (mITT) population and 89.7% (270/301) in the ITT population. For those mITT patients with genotype 3, FibroScan > 20 kPa, platelet < 150,000/µl, and FibroScan > 20 kPa and platelet < 150,000/µl, the SVR12 rates were 100% (6/6), 100% (12/12), 98.0% (144/147), 100% (7/7), respectively. Overall, 24.9% (75/301) patients experienced adverse events (AEs). The most frequent AEs (> 5%) included fatigue (9.0%) and pruritus (7.0%). Seven (2.3%) patients experienced serious AEs and two (0.7%) resulted in permanent drug discontinuation. None of them were considered as GLE/PIB-related. Conclusions: In this large-scale real-world Taiwanese cohort, 8-week GLE/PIB therapy was efficacious and well tolerated for treatment-naïve compensated cirrhosis patients. SVR12 rates were similarly high as in the clinical trials, including those with characteristics of advanced liver disease.

原文英語
頁(從 - 到)550-561
頁數12
期刊Hepatology International
卷17
發行號3
DOIs
出版品狀態已出版 - 06 2023

文獻附註

© 2023. Asian Pacific Association for the Study of the Liver.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry」主題。共同形成了獨特的指紋。

引用此